Barinthus Total Stockholder Equity vs Cash Analysis

BRNS Stock

1.09 0.03 2.68%

Barinthus Biotherapeutics financial indicator trend analysis is way more than just evaluating Barinthus Biotherapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Barinthus Biotherapeutics is a good investment. Please check the relationship between Barinthus Biotherapeutics Total Stockholder Equity and its Cash accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Barinthus Biotherapeutics plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Total Stockholder Equity vs Cash

Total Stockholder Equity vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Barinthus Biotherapeutics Total Stockholder Equity account and Cash. At this time, the significance of the direction appears to have totally related.

The correlation between Barinthus Biotherapeutics' Total Stockholder Equity and Cash is 0.99. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Cash in the same time period over historical financial statements of Barinthus Biotherapeutics plc, assuming nothing else is changed. The correlation between historical values of Barinthus Biotherapeutics' Total Stockholder Equity and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Barinthus Biotherapeutics plc are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Total Stockholder Equity i.e., Barinthus Biotherapeutics' Total Stockholder Equity and Cash go up and down completely randomly.

Correlation Coefficient

0.99

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Cash

Cash refers to the most liquid asset of Barinthus Biotherapeutics, which is listed under current asset account on Barinthus Biotherapeutics plc balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Barinthus Biotherapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Barinthus Biotherapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most indicators from Barinthus Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Barinthus Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Barinthus Biotherapeutics plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Barinthus Biotherapeutics' Enterprise Value Over EBITDA is comparatively stable compared to the past year. Enterprise Value Multiple is likely to gain to 0.90 in 2025, whereas Tax Provision is likely to drop (46.2 K) in 2025.

	2022	2023	2024	2025 (projected)
Interest Expense	19K	28K	53K	50.4K
Depreciation And Amortization	5.5M	5.5M	5.8M	3.3M

Interest Expense Depreciation And Amortization

Barinthus Biotherapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock
Total Assets		0.24	0.97	0.87	0.99	0.93	0.89	0.42	-0.99	-0.73	-0.73	1.0	0.98	1.0	0.82	0.92	0.26	-0.62	0.86	0.91	0.95	-0.49	1.0	0.81	1.0	0.94
Short Long Term Debt Total	0.24		0.29	0.34	0.13	0.18	0.21	0.2	-0.11	-0.29	0.03	0.26	0.18	0.26	0.14	0.21	-0.84	0.55	0.21	0.16	0.15	0.69	0.24	0.22	0.26	0.22
Other Current Liab	0.97	0.29		0.94	0.96	0.96	0.96	0.59	-0.93	-0.84	-0.83	0.95	0.99	0.95	0.86	0.95	0.27	-0.63	0.95	0.89	0.98	-0.49	0.97	0.92	0.96	0.97
Total Current Liabilities	0.87	0.34	0.94		0.87	0.96	0.89	0.72	-0.82	-0.93	-0.78	0.86	0.88	0.86	0.94	0.95	0.22	-0.58	0.96	0.71	0.96	-0.42	0.88	0.95	0.87	0.98
Total Stockholder Equity	0.99	0.13	0.96	0.87		0.94	0.89	0.42	-0.99	-0.72	-0.76	0.99	0.99	0.99	0.83	0.93	0.37	-0.7	0.87	0.91	0.96	-0.59	0.99	0.82	0.99	0.94
Net Tangible Assets	0.93	0.18	0.96	0.96	0.94		0.9	0.69	-0.9	-0.91	-0.84	0.92	0.94	0.92	0.91	0.93	0.37	-0.71	0.94	0.76	0.98	-0.58	0.93	0.91	0.92	0.98
Property Plant And Equipment Net	0.89	0.21	0.96	0.89	0.89	0.9		0.62	-0.84	-0.8	-0.81	0.85	0.95	0.85	0.84	0.9	0.34	-0.66	0.96	0.89	0.93	-0.54	0.89	0.96	0.86	0.91
Current Deferred Revenue	0.42	0.2	0.59	0.72	0.42	0.69	0.62		-0.34	-0.91	-0.77	0.38	0.49	0.38	0.59	0.54	0.22	-0.42	0.75	0.24	0.61	-0.33	0.42	0.77	0.4	0.63
Net Debt	-0.99	-0.11	-0.93	-0.82	-0.99	-0.9	-0.84	-0.34		0.66	0.72	-0.99	-0.97	-0.99	-0.8	-0.91	-0.37	0.69	-0.81	-0.91	-0.94	0.58	-0.99	-0.76	-0.99	-0.91
Retained Earnings	-0.73	-0.29	-0.84	-0.93	-0.72	-0.91	-0.8	-0.91	0.66		0.82	-0.71	-0.76	-0.71	-0.84	-0.8	-0.23	0.55	-0.91	-0.51	-0.85	0.41	-0.73	-0.9	-0.72	-0.88
Accounts Payable	-0.73	0.03	-0.83	-0.78	-0.76	-0.84	-0.81	-0.77	0.72	0.82		-0.7	-0.8	-0.7	-0.64	-0.78	-0.51	0.75	-0.87	-0.67	-0.84	0.66	-0.74	-0.84	-0.71	-0.82
Cash	1.0	0.26	0.95	0.86	0.99	0.92	0.85	0.38	-0.99	-0.71	-0.7		0.97	1.0	0.8	0.9	0.23	-0.59	0.82	0.89	0.94	-0.46	1.0	0.78	1.0	0.92
Non Current Assets Total	0.98	0.18	0.99	0.88	0.99	0.94	0.95	0.49	-0.97	-0.76	-0.8	0.97		0.97	0.83	0.93	0.34	-0.69	0.91	0.94	0.97	-0.56	0.99	0.87	0.97	0.95
Cash And Short Term Investments	1.0	0.26	0.95	0.86	0.99	0.92	0.85	0.38	-0.99	-0.71	-0.7	1.0	0.97		0.8	0.9	0.23	-0.59	0.82	0.89	0.94	-0.46	1.0	0.78	1.0	0.92
Net Receivables	0.82	0.14	0.86	0.94	0.83	0.91	0.84	0.59	-0.8	-0.84	-0.64	0.8	0.83	0.8		0.91	0.39	-0.69	0.89	0.66	0.91	-0.55	0.83	0.89	0.81	0.93
Common Stock Total Equity	0.92	0.21	0.95	0.95	0.93	0.93	0.9	0.54	-0.91	-0.8	-0.78	0.9	0.93	0.9	0.91		0.34	-0.68	0.94	0.84	0.98	-0.53	0.93	0.92	0.91	0.98
Common Stock Shares Outstanding	0.26	-0.84	0.27	0.22	0.37	0.37	0.34	0.22	-0.37	-0.23	-0.51	0.23	0.34	0.23	0.39	0.34		-0.91	0.36	0.29	0.4	-0.97	0.27	0.34	0.24	0.34
Non Current Liabilities Total	-0.62	0.55	-0.63	-0.58	-0.7	-0.71	-0.66	-0.42	0.69	0.55	0.75	-0.59	-0.69	-0.59	-0.69	-0.68	-0.91		-0.68	-0.59	-0.74	0.98	-0.63	-0.66	-0.6	-0.69
Capital Lease Obligations	0.86	0.21	0.95	0.96	0.87	0.94	0.96	0.75	-0.81	-0.91	-0.87	0.82	0.91	0.82	0.89	0.94	0.36	-0.68		0.78	0.96	-0.54	0.86	0.99	0.84	0.96
Other Current Assets	0.91	0.16	0.89	0.71	0.91	0.76	0.89	0.24	-0.91	-0.51	-0.67	0.89	0.94	0.89	0.66	0.84	0.29	-0.59	0.78		0.85	-0.49	0.91	0.76	0.89	0.81
Other Stockholder Equity	0.95	0.15	0.98	0.96	0.96	0.98	0.93	0.61	-0.94	-0.85	-0.84	0.94	0.97	0.94	0.91	0.98	0.4	-0.74	0.96	0.85		-0.6	0.96	0.93	0.94	0.99
Total Liab	-0.49	0.69	-0.49	-0.42	-0.59	-0.58	-0.54	-0.33	0.58	0.41	0.66	-0.46	-0.56	-0.46	-0.55	-0.53	-0.97	0.98	-0.54	-0.49	-0.6		-0.5	-0.52	-0.47	-0.54
Net Invested Capital	1.0	0.24	0.97	0.88	0.99	0.93	0.89	0.42	-0.99	-0.73	-0.74	1.0	0.99	1.0	0.83	0.93	0.27	-0.63	0.86	0.91	0.96	-0.5		0.82	1.0	0.94
Property Plant And Equipment Gross	0.81	0.22	0.92	0.95	0.82	0.91	0.96	0.77	-0.76	-0.9	-0.84	0.78	0.87	0.78	0.89	0.92	0.34	-0.66	0.99	0.76	0.93	-0.52	0.82		0.79	0.93
Total Current Assets	1.0	0.26	0.96	0.87	0.99	0.92	0.86	0.4	-0.99	-0.72	-0.71	1.0	0.97	1.0	0.81	0.91	0.24	-0.6	0.84	0.89	0.94	-0.47	1.0	0.79		0.93
Capital Stock	0.94	0.22	0.97	0.98	0.94	0.98	0.91	0.63	-0.91	-0.88	-0.82	0.92	0.95	0.92	0.93	0.98	0.34	-0.69	0.96	0.81	0.99	-0.54	0.94	0.93	0.93

Click cells to compare fundamentals

Barinthus Biotherapeutics Account Relationship Matchups

Barinthus Biotherapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	50.7M	280.7M	270.2M	214.5M	160.3M	182.5M
Short Long Term Debt Total	46.4M	7.2M	8.8M	13.0M	12.0M	11.9M
Other Current Liab	2.5M	7.9M	8.1M	9.2M	7.1M	6.6M
Total Current Liabilities	7.6M	11.2M	12.2M	12.6M	15.7M	11.9M
Total Stockholder Equity	(37.3M)	252.1M	242.9M	186.8M	130.0M	137.9M
Property Plant And Equipment Net	2.8M	9.1M	15.7M	19.4M	11.8M	11.3M
Current Deferred Revenue	245K	182K	0.0	1.7M	2.0M	2.1M
Net Debt	3.1M	(206.8M)	(185.6M)	(129.1M)	(98.7M)	(103.6M)
Retained Earnings	(57.7M)	(108.6M)	(103.2M)	(176.6M)	(237.7M)	(225.8M)
Accounts Payable	4.7M	2.4M	3.7M	1.6M	2.5M	2.5M
Cash	43.3M	214.1M	194.4M	142.1M	110.7M	131.2M
Non Current Assets Total	2.8M	54.0M	57.2M	57.6M	34.6M	38.3M
Cash And Short Term Investments	43.3M	214.1M	194.4M	142.1M	110.7M	131.2M
Net Receivables	3.2M	7.1M	12.2M	7.9M	13.0M	8.7M
Common Stock Shares Outstanding	47.6K	37.2M	38.2M	38.4M	39.3M	34.3M
Liabilities And Stockholders Equity	50.7M	280.7M	270.2M	214.5M	160.3M	182.5M
Non Current Liabilities Total	79.9M	17.0M	14.8M	14.9M	14.5M	23.5M
Capital Lease Obligations	1.7M	7.1M	8.8M	13.0M	12.0M	8.1M
Other Current Assets	1.1M	5.6M	6.5M	6.9M	2.1M	2.0M
Other Stockholder Equity	21.7M	369.1M	379.5M	386.7M	393.6M	293.4M
Total Liab	87.6M	28.2M	27.0M	27.5M	30.2M	32.2M
Net Invested Capital	7.4M	252.3M	242.9M	186.8M	130.0M	146.1M
Property Plant And Equipment Gross	2.8M	9.1M	15.7M	23.1M	21.2M	13.7M
Total Current Assets	47.9M	226.8M	213.0M	156.9M	125.7M	144.2M
Accumulated Other Comprehensive Income	(1.2M)	(8.5M)	(33.5M)	(23.3M)	(25.9M)	(24.6M)
Net Working Capital	40.3M	215.6M	200.8M	144.3M	110.1M	132.3M
Short Term Debt	192K	682K	433K	1.8M	1.9M	2.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Barinthus Stock Analysis

When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC